Understanding cognitive decline in older adults with psychotic disorders over 35 years
Official title: Trajectories and Determinants of Cognitive Decline in Psychotic Disorders Over 35 Years
Funded at State University New York Stony Brook · NIH-11009583 · Data updated 2026-11-12
This study is looking at how thinking and memory skills change as older adults with psychotic disorders age, to better understand when these changes start and how they affect daily life, and it’s for people aged 65 and up who have experienced psychosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | January 15, 2024 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $680,612 |
| NIH project number | 5R01MH135119-02 |
| Project ID | NIH-11009583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who have a history of psychotic disorders.
✕Less likely to help
Patients who are younger than 65 or do not have a diagnosis of a psychotic disorder may not benefit from this research.
What this research studies
This research investigates how cognitive decline progresses in individuals with psychotic disorders as they age, particularly focusing on those who are 65 years and older. By analyzing data from a long-term study that has followed participants since their first episode of psychosis, the research aims to identify when cognitive decline begins, its causes, and its effects on daily functioning. Participants will undergo comprehensive evaluations, including cognitive tests and medical assessments, to gather insights into their mental health trajectory. The study seeks to compare the cognitive decline of those with psychotic disorders to that of matched individuals without such disorders.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of cognitive decline in older adults with psychotic disorders, potentially enhancing their quality of life.
How similar studies have gone: Previous research has shown promising results in understanding cognitive decline in psychotic disorders, but this specific long-term approach is relatively novel.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Kotov, Roman I — State University New York Stony Brook
- Study coordinator: Kotov, Roman I
Related research
Other NIH-funded projects on the same topics.
-
35-year memory and thinking changes in people with psychosis
This project tracks memory and thinking over 35 years in people who had psychotic disorders and in similar adults without psychosis as they reach older age.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Neural Circuitry Resilience in Psychotic Disorders
Researchers are using ultra-high-field brain scans to understand how brain networks in people with schizophrenia adapt over time, with the goal of finding new ways to improve thinking and daily functioning.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.